| Name | Title | Contact Details |
|---|---|---|
Kelly Choi |
Senior Vice President, Marketing and Product Management | Profile |
Diana King |
Vice President of Field Service and Customer Support | Profile |
Lalitta Ghandikota |
Head of Global Talent | Profile |
Brian Stolz |
Chief People Officer | Profile |
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
MicroDose Therapeutx is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The FidoCure® team is committed to introducing the therapies that have been successfully used to treat humans with cancer into the world of veterinary medicine. Currently, cancer care for dogs lags behind human cancer care by about 20 years. Our goal is to improve the outcome for canine cancer patients. We are the first and only company to offer the information needed to work with your veterinarian on targeted medicines for dogs with cancer.
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
J. Craig Venter Institute (JVCI) is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.